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An 8-year-old, neutered male French Bulldog was presented with a 2-day history of 21 
intermittent vomiting, reduced appetite and recent rapid development of multiple cutaneous 22 
masses over the head and neck regions. On presentation, the patient had a moderate volume 23 
of pericardial and bilateral pleural effusion. Echocardiography demonstrated irregular, 24 




infiltrative intramyocardial disease. Cytological examination of fine needle aspirates from 26 
one of the cutaneous masses confirmed a mast cell tumour. Pericardial fluid analysis revealed 27 
a haemorrhagic neoplastic effusion due to mast cell neoplasia. Histopathological and 28 
immunohistochemical examination of tissues obtained post mortem, confirmed a high-grade 29 
cutaneous mast cell tumour with metastasis to the heart, pericardium, mediastinum and 30 
spleen. No metastatic disease was present in the submandibular lymph nodes or liver. 31 
Immunohistochemistry demonstrated KIT staining pattern 2. There was strong nuclear Ki67 32 
labelling in an average of 65.0 cells per grid and an average of three positive AgNORs per 33 
nucleus in neoplastic cells. PCR for the activating duplication mutation in exons 8 and 11 of 34 
c-Kit were negative. To the authors’ knowledge, this is the first report of a canine cutaneous 35 
mast cell tumour associated with neoplastic pericardial effusion and widespread intrathoracic 36 
metastasis. 37 
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 41 
Mast cell tumours (MCTs) are the most common canine cutaneous neoplasia and vary widely 42 
in their biological behaviour. Cutaneous and subcutaneous locations are most common but 43 
other primary sites include tissues of the gastrointestinal tract, including oral cavity. There 44 
are several reports of presumed primary intrathoracic MCTs (Cowgill and Neel, 2008; 45 
Campbell et al, 2017; Cartagena-Albertus et al, 2019). Metastasis is often to local lymph 46 
nodes, liver, spleen and, rarely, bone marrow and lungs. The c-Kit gene is implicated in the 47 
pathogenesis of canine MCTs and mutations in this gene have been linked to tumour 48 
aggressiveness (Preziosi et al, 2004). The proto-oncogene c-Kit encodes KIT, a receptor 49 




somatic mutations in c-Kit have been described, most commonly in exon 11 (affecting the 51 
juxtamembrane domain of the protein), or in exons 8 or 9 (affecting the extracellular domain) 52 
(Ma et al, 1999). These mutations result in constitutive activation of KIT and subsequent 53 
proliferation, differentiation and survival of neoplastic mast cells. The prognosis of canine 54 
MCT depends on a number of factors, with tumour grade and stage of disease being the most 55 
influential. Cutaneous MCTs are routinely graded according to the Patnaik system (Patnaik et 56 
al, 1984), as grade 1, 2 or 3, or the Kiupel system (Kiupel et al, 2011), in which tumours are 57 
categorised as low or high grade, depending on their histological features. The histological 58 
grade of cutaneous MCTs is prognostic; it is well documented that dogs with Patnaik grade 3 59 
tumours have a significantly shorter overall survival time compared to those with Patnaik 60 
grade 1 and 2 tumours (Patnaik et al, 1984; Takeuchi et al, 2013). Similarly, dogs with 61 
Kiupel high-grade tumours have significantly shorter overall survival times and progression-62 
free survival times compared to those with low-grade tumours (Kiupel et al, 2011; Vascellari 63 
et al, 2013). Increasing stage of disease is also correlated with a worse prognosis, with a 64 
median survival time of just 110 days in dogs with distant metastatic (stage IV) disease 65 
(Murphy et al, 2006; Pizzoni et al, 2018).  66 
 67 
An 8-year-old, neutered male French bulldog was referred to the Royal Veterinary 68 
College’s Queen Mother Hospital for Animals with a two-day history of intermittent 69 
vomiting, hyporexia and recent rapid development of multiple cutaneous masses (within the 70 
preceding 3 days). On presentation, physical examination revealed tachycardia (140 beats per 71 
minute), muffled heart sounds, tachypnoea (32 breaths per minute), dyspnoea and multiple 72 
cutaneous masses on the dorsal head, neck and cranial thoracic regions. Haematological 73 
abnormalities included a mild neutrophilia (12.91 × 109/L; reference interval [RI], 3.0 — 11.5 74 




haemoconcentration (packed cell volume (PCV) 60%; RI, 37 × 55, haemoglobin 76 
concentration 20.8 g/dl; RI, 12—18). Blood smear examination was unremarkable. Serum 77 
biochemistry examination revealed only a moderate hypochloraemia (88.8 mmol/L; RI: 78 
100—116 mmol/L). Ultrasound assessment revealed moderate pericardial and bilateral 79 
pleural effusion although no peritoneal effusion was present. Echocardiography demonstrated 80 
irregular, heterogeneous thickening of the right ventricular free wall and right atrial wall, 81 
consistent with infiltrative intramyocardial disease. Electrocardiography confirmed sinus 82 
arrhythmia with first-degree atrioventricular block.  83 
Fine needle aspirates, obtained from one of the cutaneous masses, contained abundant 84 
individual neoplastic mast cells, occasional erythrocytes, low numbers of lysed cells, and a 85 
pale blue background with lipid spaces and abundant mast cell granules. Mast cells had round 86 
to oval nuclei (up to 20—25 µm), finely granular chromatin, multiple prominent nucleoli and 87 
a moderate amount of pale blue cytoplasm, commonly with low numbers of mast cell 88 
granules and occasional crisp vacuoles. There were mild anisokaryosis and occasional mitotic 89 
figures. Other cells included occasional dense clumps of plump spindle cells (likely 90 
fibroblasts), occasional eosinophils, neutrophils and rare macrophages. These findings were 91 
consistent with mast cell neoplasia.  92 
Upon induction of anaesthesia, prior to further investigations, the dog suffered a 93 
cardiopulmonary arrest and open-chest cardiopulmonary resuscitation was required for a 94 
successful return of spontaneous circulation. Before closing the emergency thoracotomy site, 95 
a pericardial effusion sample and tissue samples from the pericardial/mediastinal fat were 96 
obtained for cytological and histopathological examination, respectively, due to their 97 
abnormal gross appearance. The heart also appeared grossly abnormal with widespread 98 




The pericardial fluid appeared red, turbid and had a total nucleated cell concentration 100 
of 5.90 × 109/L, protein concentration of 30 g/L and a PCV of 14%. Cytological examination 101 
of direct smears of the fluid (Fig. 1) found low nucleated cellularity, moderate numbers of 102 
erythrocytes, occasional lysed cells and a clear background. Nucleated cells were dominated 103 
by poorly granulated, highly anaplastic mast cells with large nuclei (up to 30 µm), smooth to 104 
coarse chromatin, multiple prominent nucleoli and a small to moderate amount of pale to 105 
dark blue cytoplasm with low numbers of purple granules. Anisokaryosis was mild to 106 
moderate and occasional binucleation was seen. Rare mitotic figures were also observed. 107 
Other cells included low numbers of neutrophils, lymphocytes, occasional macrophages and 108 
scattered eosinophils. These findings were consistent with a haemorrhagic neoplastic effusion 109 
due to mast cell neoplasia. The mast cells in the effusion matched the appearance of those in 110 
the previously described cutaneous mass. 111 
After two days of management in the Intensive Care Unit the dog suffered a second 112 
cardiopulmonary arrest and resuscitation was not attempted. A cosmetic necropsy was 113 
requested by the owners.  114 
On gross examination the heart had multiple, random, white, raised nodules ranging 115 
from 2 × 2 mm to 11 × 10 mm that extended into the myocardium (Fig. 2). Skin samples 116 
from the right dorsal cervical and submandibular regions had moderately demarcated, 5 × 10 117 
mm to 10 × 10 mm nodules. Histologically, the skin nodules consisted of poorly demarcated, 118 
highly infiltrative, moderately cellular, high-grade mast cell tumours. Mast cells were 119 
organized in loose sheets that dissected collagen bundles and there were multifocal areas of 120 
dermal necrosis and vasculitis. Very rare eosinophils were observed scattered between the 121 
neoplastic mast cells. The neoplastic cells had moderately distinct borders, a moderate 122 
amount of pale, eosinophilic cytoplasm with one or multiple paracentral, pleomorphic nuclei. 123 




power fields (total area 2.37 mm2), equating to high-grade tumours. Sections from the heart 125 
(Fig. 3), pericardium, mediastinum and spleen contained neoplastic foci composed of poorly-126 
differentiated mast cells similar to those described in the skin. Mast cells were not 127 
metachromatic with toluidine-blue or modified Wright-Giemsa stains in any of the examined 128 
sections. The submandibular lymph nodes, lung or liver did not contain macroscopic or 129 
microscopic evidence of neoplastic mast cells.  130 
Due to the poorly differentiated appearance of the cells, immunohistochemistry for 131 
CD3, CD79, AE1AE3 (multikeratin), vimentin and KIT were performed to exclude other 132 
round cell tumours. Additionally, Ki67 immunolabelling and argyrophilic nucleolar 133 
organising regions (AgNOR) staining were performed. Immunohistochemistry demonstrated 134 
negative labelling of the neoplastic cells for CD3, CD79 and AE1AE3 antigens, whereas 135 
vimentin immunolabelling was positive. Immunohistochemical labelling for KIT was also 136 
positive and showed both a loss of peri-membrane labelling and perinuclear or stippled 137 
cytoplasmic labelling in greater than 10% of neoplastic cells, consistent with KIT labelling 138 
pattern 2 (Preziosi et al, 2004) (Fig. 4). There was strong Ki67 nuclear labelling in an average 139 
of 65.0 cells per grid and an average of three positive AgNORs per nucleus in neoplastic 140 
cells. The AgNOR × Ki67 index was 192.3. A polymerase chain reaction technique for the 141 
detection of activating duplication mutations in exons 8 and 11 of c-Kit was negative. The 142 
cytological, histological and immunohistochemical findings were consistent with mast cell 143 
neoplasia. 144 
 145 
There are no previous reports of metastasis of a cutaneous MCT to intrathoracic 146 
tissues such as the pericardium and mediastinum. A few post-mortem descriptions of cardiac 147 
involvement do exist (Walter and Rudolph, 1996; Ware and Hopper, 1999), but these reports 148 




often metastasise to regional lymph nodes prior to systemic dissemination, it is interesting 150 
that with the presence of masses on the head in the present case, no metastatic disease was 151 
detected in the submandibular lymph nodes. As the metastatic pattern of head and oral 152 
tumours can be unpredictable (Skinner et al, 2017), it is possible the masses present on this 153 
patient’s head drained through the retropharyngeal lymph nodes instead, which were not 154 
sampled. The intrathoracic metastatic disease may have developed secondary to the 155 
cutaneous tumours present on the patient’s neck or thorax, which would have drained via 156 
other regional lymph nodes, such as the superficial cervical or axillary lymph nodes and 157 
which were also not sampled.  158 
A neoplastic pericardial effusion secondary to mast cell neoplasia has not been 159 
previously reported. Exfoliation of neoplastic cells into a body cavity can cause highly 160 
cellular effusions, with lymphoma being the most common cause of neoplastic effusions in 161 
dogs and cats (Dempsey and Ewing, 2011). Cavity effusions in dogs with MCTs are 162 
uncommon and seen primarily in cases with visceral involvement; both pleural and peritoneal 163 
effusions have been reported (Cowgill and Neel, 2008; Harris et al, 2013). Effusions 164 
secondary to mast cell neoplasia in dogs can be highly eosinophilic (Harris et al, 2013), likely 165 
due to the development and chemotaxis of eosinophils secondary to prostaglandin D2, 166 
leukotriene, IL-3, IL-5 and GM-CSF secreted from activated mast cells (Stone et al, 2010). 167 
Only occasional eosinophils were seen in the pericardial effusion of this case and very low 168 
numbers were observed on histopathology of the affected tissues.  169 
The cutaneous mass in the described patient was consistent with a Patnaik grade 170 
3/Kiupel high-grade MCT. This is unusual as French bulldogs are more likely to develop 171 
Patnaik grade 1 cutaneous MCTs (Śmiech et al, 2017). Immunohistochemistry for KIT and 172 
vimentin was important to confirm the histopathological diagnosis of metastatic mast cell 173 




Additionally, toluidine blue and Giemsa staining did not demonstrate metachromasia. 175 
However, the mast cell granules, despite being sparse, stained well with modified Wright-176 
Giemsa stain during the cytological assessment of the cutaneous masses and pericardial 177 
effusion, emphasising the importance of cytological examination of mast cell neoplasia. 178 
Activating mutations in exons 8, 9 and 11 of the c-Kit gene are common in canine MCTs, 179 
with one study demonstrating mutations in 26.2% of tumours (Letard et al, 2008). C-Kit 180 
mutations are also significantly associated with higher grade MCTs (Vozdova et al, 2019) 181 
and are associated with decreased disease-free interval, increased risk of tumour recurrence 182 
and decreased overall survival time (Webster et al, 2006). Despite the high-grade designation 183 
in this case, PCR for the activating duplication mutations in exons 8 and 11 of c-Kit were 184 
negative. C-Kit gene sequencing was not performed and it is possible that other activating 185 
mutations were present in this MCT. 186 
Proliferation markers, such as Ki67 and AgNOR, have been assessed in canine MCTs 187 
and are associated with prognosis (Webster et al, 2007). Mast cell tumours with a Ki67 index 188 
>23 positive cells per grid have a significantly increased risk of local recurrence, metastasis 189 
and MCT-related death. Similar findings were observed in MCTs with increased AgNOR 190 
counts. An AgNOR × Ki67 index >54 has been associated with increased risk of local 191 
recurrence and MCT-related death (Webster et al, 2007). The KIT expression pattern is also 192 
associated with prognosis. Normally, KIT is expressed in the cell membrane of mast cells 193 
(Reguera et al, 2000), which is classified as KIT staining pattern 1. In some neoplastic mast 194 
cells KIT is expressed focally (staining pattern 2) or diffusely (staining pattern 3) throughout 195 
the cytoplasm. Increased cytoplasmic KIT expression is associated with increased risk of 196 
local recurrence and reduced overall survival (Kiupel et al, 2004). In the case presented here, 197 
the Ki67 index was very high (65 cells per grid) in addition to an elevated AgNOR count (3.0 198 




2. These results demonstrate an aggressive phenotype, which correlates with the cytological 200 
appearance and histopathological grade of the tumour, as well as the dog’s clinical 201 
presentation. 202 
In summary, to the authors’ knowledge, this is the first report describing a canine 203 
cutaneous MCT associated with a neoplastic pericardial effusion and widespread intra-204 
thoracic metastasis.  205 
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FIGURE LEGENDS 285 
Fig. 1. Dog, pericardial effusion, mast cell tumour. Poorly granulated neoplastic mast cells 286 
have nuclei up to 20 µm in diameter, smooth chromatin, prominent nucleoli and small to 287 
moderate amounts of mid—dark blue cytoplasm, with low numbers of fine purple granules 288 
and punctate vacuoles. Note mitotic figure (arrow). Modified Wright’s stain. Bar, 20 μm. 289 
 290 
Fig. 2. Dog, heart, mast cell tumour. Multiple random white nodules expand the right and left 291 
ventricles, left auricle, aorta and pulmonary artery. Bar, 2 cm. 292 
 293 
Fig. 3. Dog, heart, mast cell tumour. Sheets of neoplastic mast cells dissect myocardial fibres. 294 
There is moderate to marked anisocytosis and anisokaryosis and frequent mitoses. No visible 295 





Fig. 4. Dog, heart, mast cell tumour. Neoplastic mast cells exhibit a cytoplasmic perinuclear 298 
KIT labelling pattern (KIT labelling pattern 2). IHC. Bar, 20 μm. 299 
